The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer

OncoImmunology

Volumn 3, Issue 11, 2014, Pages e967142-1-e967142-7

  Lee, Ming Ching ^a,b   Buitrago, Daniel H ^a   Kadota, Kyuichi ^a   Ujiie, Hideki ^a   Woo, Kaitlin ^a   Sima, Camelia S ^a   Travis, William D ^a   Jones, David R ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

forkhead box P3; non small cell lung cancer; octogenarians; old age; tumor infiltrating lymphocytes

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

AGED; ARTICLE; CELL INFILTRATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; TISSUE MICROARRAY; TUMOR IMMUNE MICROENVIRONMENT; TUMOR MICROENVIRONMENT; VERY ELDERLY;

EID: 84938631463     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.967142     Document Type: Article

References (44)

1. B.K.Edwards, H.L.Howe, L.A.Ries, M.J.Thun, H.M.Rosenberg, R.Yancik, P.A.Wingo, A.Jemal, E.G.Feigal. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002; 94(10):2766-92; PMID:12173348; http://dx.doi.org/10.1002/cncr.10593
2. T.K.Owonikoko, C.C.Ragin, C.P.Belani, A.B.Oton, W.E.Gooding, E.Taioli, S.S.Ramalingam. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J clin oncol 2007; 25(35):5570-7; PMID:18065729; http://dx.doi.org/10.1200/JCO.2007.12.5435
3. C.A.Werner. The Older Population: 2010. The 2010 Census Briefs 2011.
4. C.A.van Iersel, H.J.de Koning, G.Draisma, W.P.Mali, E.T.Scholten, K.Nackaerts, M.Prokop, J.D.Habbema, M.Oudkerk, R.J.van Klaveren. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007; 120(4):868-74; PMID:17131307; http://dx.doi.org/10.1002/ijc.22134
5. National Lung Screening Trial Research T, D.R.Aberle, A.M.Adams, C.D.Berg, W.C.Black, J.D.Clapp, R.M.Fagerstrom, I.F.Gareen, C.Gatsonis, P.M.Marcus, Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365(5):395-409; PMID:21714641; http://dx.doi.org/10.1056/NEJMoa1102873
6. National Lung Screening Trial Research Team, D.R.Aberle, C.D.Berg, W.C.Black, T.R.Church, R.M.Fagerstrom, B.Galen, I.F.Gareen, C.Gatsonis, J.Goldin, The national lung screening trial: overview and study design. Radiology 2011; 258(1):243-53; PMID:21045183; http://dx.doi.org/10.1148/radiol.10091808
7. A.G.Sacher, L.W.Le, N.B.Leighl, L.E.Coate. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol 2013; 8(3):366-8; PMID:23407560; http://dx.doi.org/10.1097/JTO.0b013e31827e2145
8. K.S.Scher, A.Hurria. Under-representation of older adults in cancer registration trials: known problem, little progress. J clin oncol 2012; 30(17):2036-8; PMID:22547597; http://dx.doi.org/10.1200/JCO.2012.41.6727
9. A.G.Pallis, A.Ring, C.Fortpied, B.Penninckx, M.C.Van Nes, U.Wedding, G.Vonminckwitz, C.D.Johnson, L.Wyld, A.Timmer-Bonte, EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol 2011; 22(8):1922-6; PMID:21266517; http://dx.doi.org/10.1093/annonc/mdq687
10. K.Dorshkind, E.Montecino-Rodriguez, R.A.Signer. The ageing immune system: is it ever too old to become young again? Nat Rev Immunol 2009; 9(1):57-62; PMID:19104499; http://dx.doi.org/10.1038/nri2471
11. K.Naylor, G.Li, A.N.Vallejo, W.W.Lee, K.Koetz, E.Bryl, J.Witkowski, J.Fulbright, C.M.Weyand, J.J.Goronzy. The influence of age on T cell generation and TCR diversity. J Immunol 2005; 174(11):7446-52; PMID:15905594; http://dx.doi.org/10.4049/jimmunol.174.11.7446
12. G.Pawelec, E.Derhovanessian, A.Larbi. Immunosenescence and cancer. Crit Rev Oncol Hematol 2010; 75(2):165-72; PMID:20656212; http://dx.doi.org/10.1016/j.critrevonc.2010.06.012
13. C.E.Ruby, A.D.Weinberg. OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. J Immunol 2009; 182(3):1481-9; PMID:19155495; http://dx.doi.org/10.4049/jimmunol.182.3.1481
14. M.Provinciali, K.Argentati, A.Tibaldi. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 2000; 7(7):624-32; PMID:10819579; http://dx.doi.org/10.1038/sj.gt.3301131
15. J.Galon, A.Costes, F.Sanchez-Cabo, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pagès, M.Tosolini, M.Camus, A.Berger, P.Wind, F.Zinzindohoué, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313(5795):1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
16. B.Mlecnik, M.Tosolini, A.Kirilovsky, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pagès, M.Tosolini, M.Camus, A.Berger, P.Wind, Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29(6):610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425
17. F.Pages, A.Berger, M.Camus, F.Sanchez-Cabo, A.Costes, R.Molidor, B.Mlecnik, A.Kirilovsky, M.Nilsson, D.Damotte, Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353(25):2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424
18. L.Zhang, J.R.Conejo-Garcia, D.Katsaros, P.A.Gimotty, M.Massobrio, G.Regnani, A.Makrigiannakis, H.Gray, K.Schlienger, M.N.Liebman, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348(3):203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177
19. S.M.Mahmoud, E.C.Paish, D.G.Powe, R.D.Macmillan, M.J.Grainge, A.H.Lee, I.O.Ellis, A.R.Green. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29(15):1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037
20. K.Suzuki, K.Kadota, C.S.Sima, J.Nitadori, V.W.Rusch, W.D.Travis, M.Sadelain, P.S.Adusumilli, Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3CD3 ratio are independent predictors of recurrence. J Clin Oncol 2013; 31(4):490-8; PMID:23269987; http://dx.doi.org/10.1200/JCO.2012.45.2052
21. A.J.Bograd, K.Suzuki, E.Vertes, C.Colovos, E.A.Morales, M.Sadelain, P.S.Adusumilli. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011; 60(11):1509-27; PMID:21913025; http://dx.doi.org/10.1007/s00262-011-1103-6
22. K.Suzuki, S.S.Kachala, K.Kadota, R.Shen, Mo Q, D.G.Beer, V.W.Rusch, W.D.Travis, P.S.Adusumilli. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011; 17(16):5247-56; PMID:21659461; http://dx.doi.org/10.1158/1078-0432.CCR-10-2805
23. K.Suzuki, K.Kadota, C.S.Sima, M.Sadelain, V.W.Rusch, W.D.Travis, P.S.Adusumilli, Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother 2011; 60(12):1721-8; PMID:21769693; http://dx.doi.org/10.1007/s00262-011-1073-8
24. Y.Nakakubo, M.Miyamoto, Y.Cho, Y.Hida, T.Oshikiri, M.Suzuoki, K.Hiraoka, T.Itoh, S.Kondo, H.Katoh. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003; 89(9):1736-42; PMID:14583778; http://dx.doi.org/10.1038/sj.bjc.6601331
25. O.Wakabayashi, K.Yamazaki, S.Oizumi, F.Hommura, I.Kinoshita, S.Ogura, H.Dosaka-Akita, M.Nishimura. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003; 94(11):1003-9; PMID:14611679; http://dx.doi.org/10.1111/j.1349-7006.2003.tb01392.x
26. K.Shimizu, M.Nakata, Y.Hirami, T.Yukawa, A.Maeda, K.Tanemoto. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010; 5(5):585-90; PMID:20234320
27. F.A.Sinicrope, R.L.Rego, S.M.Ansell, K.L.Knutson, N.R.Foster, D.J.Sargent. Intraepithelial effector (CD3+)regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137(4):1270-9; PMID:19577568; http://dx.doi.org/10.1053/j.gastro.2009.06.053
28. R.Ng, R.de Boer, M.D.Green. Undertreatment of elderly patients with non-small-cell lung cancer. Clin Lung Cancer 2005; 7(3):168-74; PMID:16354310; http://dx.doi.org/10.3816/CLC.2005.n.031
29. S.Sawada, E.Komori, N.Nogami, A.Bessho, Y.Segawa, T.Shinkai, M.Nakata, M.Yamashita. Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition. Chest 2005; 128(3):1557-63; PMID:16162758; http://dx.doi.org/10.1378/chest.128.3.1557
30. E.M.Blanchard, K.Arnaoutakis, P.J.Hesketh. Lung cancer in octogenarians. J Thorac Oncol 2010; 5(6):909-16; PMID:20521358; http://dx.doi.org/10.1097/JTO.0b013e3181d89b48
31. B.Goodgame, A.Viswanathan, J.Zoole, F.Gao, C.R.Miller, J.Subramanian, B.F.Meyers, A.G.Patterson, R.Govindan. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol 2009; 4(11):1370-4; PMID:19692932; http://dx.doi.org/10.1097/JTO.0b013e3181b6bc1b
32. T.Hanagiri, H.Muranaka, M.Hashimoto, A.Nagashima, K.Yasumoto. Results of surgical treatment of lung cancer in octogenarians. Lung Cancer 1999; 23(2):129-33; PMID:10217616; http://dx.doi.org/10.1016/S0169-5002(99)00006-9
33. V.H.Murthy, H.M.Krumholz, C.P.Gross. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291(22):2720-6; PMID:15187053; http://dx.doi.org/10.1001/jama.291.22.2720
34. R.R.Jennens, G.G.Giles, R.M.Fox. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 2006; 36(4):216-20; PMID:16640737; http://dx.doi.org/10.1111/j.1445-5994.2006.01033.x
35. J.G.Aerts, J.P.Hegmans. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 2013; 73(8):2381-8; PMID:23580578; http://dx.doi.org/10.1158/0008-5472.CAN-12-3932
36. T.J.Welsh, R.H.Green, D.Richardson, Waller DA, K.J.O'Byrne, P.Bradding. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005; 23(35):8959-67; PMID:16219934; http://dx.doi.org/10.1200/JCO.2005.01.4910
37. J.Ma, L.Liu, G.Che, N.Yu, F.Dai, Z.You. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC cancer 2010; 10:112; PMID:20338029; http://dx.doi.org/10.1186/1471-2407-10-112
38. H.Liu, T.Zhang, J.Ye, H.Li, J.Huang, X.Li, B.Wu, X.Huang, J.Hou. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012; 61(10):1849-56; PMID:22456757; http://dx.doi.org/10.1007/s00262-012-1231-7
39. V.W.Rusch, H.D.Appelman., E.Blackstone. AJCC Cancer Staging Manual, 7th edition edn, New York, NY: Springer; 2009.
40. I.S.Sarkaria, M.F.Zakowski, D.Pham, D.Pham, M.Hezel, M.I.Ebright, S.Chuai, E.S.Venkatraman, M.G.Kris, V.W.Rusch, B.Singh. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. Ann Thorac Surg 2008; 85(1):216-23; PMID:18154814; http://dx.doi.org/10.1016/j.athoracsur.2007.07.046
41. K.Kadota, A.Bograd, J.Nitadori, L.Cherkassky, V.W.Rusch, W.D.Travis, M.Sadelain, P.S.Adusumilli. Prognostic impact of tumor-infiltrating immune cells in lung squamous cell carcinoma. J Thorac Oncol. 2013; 8(Supple 2):S378.
42. R.Chappell. Competing risk analyses: how are they different and why should you care? Clin Cancer Res 2012; 18(8):2127-9; PMID:22427347; http://dx.doi.org/10.1158/1078-0432.CCR-12-0455
43. J.J.Dignam, Q.Zhang, M.Kocherginsky. The use and interpretation of competing risks regression models. Clin Cancer Res 2012; 18(8):2301-8; PMID:22282466; http://dx.doi.org/10.1158/1078-0432.CCR-11-2097
44. R.J.Gray. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16(3):1141-54; http://dx.doi.org/10.1214/aos/1176350951